Overview

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Status:
Completed

Trial end date:
2020-08-25

Target enrollment:

Participant gender:

Summary

The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Antibodies, Monoclonal